Background
Main text
HPV/p16 positive and negative HNSCC show differences in nodal involvement
HPV negative
|
HPV positive
|
P
|
p16 negative
|
p16 positive
|
P
| ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||||
No. of patients | |||||||||||
175 | 58 | 173 | 68 | ||||||||
Gender |
p = 0.67b
|
p = 0.99b
| |||||||||
Male | 146 | 83 | 47 | 81 | 143 | 83 | 56 | 82 | |||
Female | 29 | 17 | 11 | 19 | 30 | 17 | 12 | 18 | |||
Age, years |
p = 0.031a
|
p = 0.046a
| |||||||||
Median (Range) | 59 | (57–60) | 61 | (59–65) | 59 | (57–60) | 61 | (59–64) | |||
Smoking history |
p = 0.001b
|
p = 0.004b
| |||||||||
Never | 8 | 5 | 15 | 26 | 11 | 6 | 13 | 19 | |||
Former | 20 | 11 | 11 | 19 | 22 | 13 | 11 | 16 | |||
Current | 126 | 72 | 25 | 43 | 120 | 69 | 35 | 51 | |||
Unknown | 21 | 12 | 7 | 12 | 20 | 12 | 9 | 13 | |||
Treatment |
p = 0.68b
|
p = 0.15b
| |||||||||
RT | 71 | 41 | 19 | 33 | 68 | 39 | 29 | 43 | |||
RT + CT | 97 | 55 | 34 | 59 | 100 | 58 | 33 | 49 | |||
RT + EGFR inhibitor | 5 | 3 | 2 | 3 | 3 | 2 | 4 | 6 | |||
Unknown | 2 | 1 | 3 | 5 | 2 | 1 | 2 | 3 | |||
Nodal stage* |
p = 0.014b
|
p = 0.07b
| |||||||||
N0/N1 | 80 | 45 | 16 | 28 | 78 | 45 | 25 | 37 | |||
N2/N3 | 95 | 54 | 42 | 72 | 94 | 54 | 43 | 63 | |||
Unknown | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | |||
Tumor stage* |
p = 0.025b
|
p = 0.11b
| |||||||||
T1/2 | 51 | 29 | 26 | 45 | 60 | 35 | 22 | 32 | |||
T3/4 | 122 | 70 | 31 | 53 | 112 | 65 | 45 | 66 | |||
unknown | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | |||
Disease stage* |
p = 0.28b
|
p = 0.18b
| |||||||||
I-II | 17 | 10 | 3 | 5 | 17 | 10 | 3 | 4 | |||
III-IV | 157 | 90 | 54 | 93 | 155 | 90 | 65 | 96 | |||
Unknown | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | |||
HPV |
p < 0.0001b
| ||||||||||
Negative | 150 | 87 | 16 | 24 | |||||||
Positive | 9 | 5 | 44 | 65 | |||||||
Unknown | 14 | 8 | 8 | 12 | |||||||
p16 |
p < 0.0001b
| ||||||||||
Negative | 150 | 86 | 9 | 16 | |||||||
Positive | 16 | 9 | 44 | 76 | |||||||
Unknown | 9 | 5 | 5 | 9 |
p16 represses the invasion and migration capacity of HPV positive HNSCC
p16 suppresses migration and invasion through angiogenesis in HPV positive HNSCC
VEGF low | VEGF high |
P
| |||
---|---|---|---|---|---|
No. | (%) | No. | (%) | ||
HPV |
p=0.005b
| ||||
Negative | 53 | 65 | 108 | 82 | |
Positive | 28 | 35 | 23 | 18 | |
p16 |
p=0.07b
| ||||
Negative | 53 | 66 | 99 | 77 | |
Positive | 27 | 34 | 29 | 23 |